Trials / Completed
CompletedNCT01786902
Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 4 Years – 13 Years
- Healthy volunteers
- Not accepted
Summary
Growth hormone therapy will improve the height of idiopathic short statured children. DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to non-treatment group in efficacy and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-3002 |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2013-02-08
- Last updated
- 2017-10-19
- Results posted
- 2015-05-29
Source: ClinicalTrials.gov record NCT01786902. Inclusion in this directory is not an endorsement.